190 related articles for article (PubMed ID: 11316238)
41. Urinary excretion of low-molecular-weight proteins as prognostic markers in IgA nephropathy.
Peters HP; van den Brand JA; Wetzels JF
Neth J Med; 2009 Feb; 67(2):54-61. PubMed ID: 19299847
[TBL] [Abstract][Full Text] [Related]
42. The impact of sex in primary glomerulonephritis.
Cattran DC; Reich HN; Beanlands HJ; Miller JA; Scholey JW; Troyanov S;
Nephrol Dial Transplant; 2008 Jul; 23(7):2247-53. PubMed ID: 18182409
[TBL] [Abstract][Full Text] [Related]
43. [Some metabolic and genetic risk factors and the progression of IgA nephropathy--preliminary report].
Sulikowska B; Czarny J; Rość D; Odrowaz-Sypniewska G; Manitius J; Sliwka DM
Pol Merkur Lekarski; 2006 Aug; 21(122):132-5; discussion 136. PubMed ID: 17144095
[TBL] [Abstract][Full Text] [Related]
44. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
Siu YP; Leung KT; Tong MK; Kwan TH
Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
[TBL] [Abstract][Full Text] [Related]
45. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors.
Locatelli F; Vecchio LD; Pozzi C
Nat Clin Pract Nephrol; 2006 Jan; 2(1):24-31. PubMed ID: 16932386
[TBL] [Abstract][Full Text] [Related]
46. Statins stabilize the renal function of IgA nephropathy.
Moriyama T; Oshima Y; Tanaka K; Iwasaki C; Ochi A; Itabashi M; Takei T; Uchida K; Nitta K
Ren Fail; 2014 Apr; 36(3):356-60. PubMed ID: 24341619
[TBL] [Abstract][Full Text] [Related]
47. Immunosuppressive therapy and clinical evolution in forty-nine patients with antineutrophil cytoplasmic antibody-associated glomerulonephritis.
Kokolina E; Alexopoulos E; Dimitriadis C; Vainas A; Giamalis P; Papagianni A; Ekonomidou D; Memmos D
Ann N Y Acad Sci; 2005 Jun; 1051():597-605. PubMed ID: 16127000
[TBL] [Abstract][Full Text] [Related]
48. Predictors of outcome in Henoch-Schönlein nephritis in children and adults.
Coppo R; Andrulli S; Amore A; Gianoglio B; Conti G; Peruzzi L; Locatelli F; Cagnoli L
Am J Kidney Dis; 2006 Jun; 47(6):993-1003. PubMed ID: 16731294
[TBL] [Abstract][Full Text] [Related]
49. Presentation, prognosis and outcome of IgA nephropathy in Indian adults.
Chacko B; John GT; Neelakantan N; Korula A; Balakrishnan N; Kirubakaran MG; Jacob CK
Nephrology (Carlton); 2005 Oct; 10(5):496-503. PubMed ID: 16221102
[TBL] [Abstract][Full Text] [Related]
50. Comparison of oral steroids with tonsillectomy plus steroid pulse therapy in patients with IgA nephropathy.
Hoshino Y; Moriyama T; Uchida K; Tsuchiya K; Nitta K
Clin Exp Nephrol; 2017 Aug; 21(4):617-623. PubMed ID: 27549901
[TBL] [Abstract][Full Text] [Related]
51. Combined treatment with steroids and azathioprine in IgA nephropathy: design of a prospective randomised multicentre trial.
Locatelli F; Pozzi C; Del Vecchio L; Andrulli S; Pani A; Fogazzi G; Altieri P; Ponticelli C
J Nephrol; 1999; 12(5):308-11. PubMed ID: 10630693
[TBL] [Abstract][Full Text] [Related]
52. IGA nephropathy - Are intravenous steroid pulses more effective than oral steroids in relapse prevention?
Laranjinha I; Matias P; Cassis J; Branco P; Ramos S; Barata JD; Weigert A
Nefrologia (Engl Ed); 2018; 38(4):355-360. PubMed ID: 29129388
[TBL] [Abstract][Full Text] [Related]
53. Comparison of steroids and angiotensin receptor blockers for patients with advanced IgA nephropathy and impaired renal function.
Moriyama T; Amemiya N; Ochi A; Tsuruta Y; Shimizu A; Itabashi M; Takei T; Uchida K; Nitta K
Am J Nephrol; 2011; 34(3):233-40. PubMed ID: 21778707
[TBL] [Abstract][Full Text] [Related]
54. Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases.
Kobayashi Y; Fujii K; Hiki Y; Tateno S
Q J Med; 1986 Oct; 61(234):935-43. PubMed ID: 3628707
[TBL] [Abstract][Full Text] [Related]
55. Assessment of progression of chronic renal failure--using reciprocal of serum creatinine.
Muthusethupathi MA; Kumar SS; Sekaran L
J Assoc Physicians India; 1989 Mar; 37(3):213-6. PubMed ID: 2768164
[TBL] [Abstract][Full Text] [Related]
56. Corticosteroids in IgA nephropathy: a randomised controlled trial.
Pozzi C; Bolasco PG; Fogazzi GB; Andrulli S; Altieri P; Ponticelli C; Locatelli F
Lancet; 1999 Mar; 353(9156):883-7. PubMed ID: 10093981
[TBL] [Abstract][Full Text] [Related]
57. Initial treatment with pulse methylprednisolone followed by short-term prednisolone and tonsillectomy for childhood IgA nephropathy.
Yamada A; Fujinaga S; Sakuraya K; Satoshi A; Hirano D
Clin Exp Nephrol; 2018 Oct; 22(5):1143-1149. PubMed ID: 29520517
[TBL] [Abstract][Full Text] [Related]
58. Prognostic relevance of clinical and histological features in IgA nephropathy treated with steroid and angiotensin receptor blockers.
Choi S; Lee D; Jeong KH; Moon JY; Lee SH; Lee TW; Ihm CG
Clin Nephrol; 2009 Nov; 72(5):353-9. PubMed ID: 19863877
[TBL] [Abstract][Full Text] [Related]
59. Role of proteinuria reduction in the progression of IgA nephropathy.
Locatelli F; Pozzi C; Del Vecchio L; Bolasco PG; Fogazzi GB; Andrulli S; Melis P; Altieri P; Ponticelli C
Ren Fail; 2001; 23(3-4):495-505. PubMed ID: 11499564
[TBL] [Abstract][Full Text] [Related]
60. Tonsillectomy and steroid pulse therapy for recurrent IgA nephropathy in renal allograft.
Tsuchiya T; Ito S; Yamaguchi Y; Moriyama Y; Ehara H; Deguchi T
Clin Nephrol; 2010 Jan; 73(1):68-71. PubMed ID: 20040355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
